A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Recruiting · NCT06022029 · Registry updated 2025-12-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | B-cell neoplasm, Bites and Stings, Cancer of the Uterine Cervix, Chemically-Induced Disorders, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, Uveal Neoplasms, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, cervix disorder, diffuse large B-cell lymphoma, epithelial neoplasm, eye disorder, female reproductive system disorder, female reproductive system neoplasm, follicular lymphoma, head and neck squamous cell carcinoma, immune system disorder, immunoproliferative disorder, in situ carcinoma, injury, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, melanocytic neoplasm, melanoma, metastatic malignant neoplasm, neoplasm, neuroendocrine neoplasm, ocular cancer, poisoning, primitive neuroectodermal tumor, skin disorder, skin neoplasm, squamous cell carcinoma, triple-negative breast carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder, uveal disorder, uveal melanoma | Recruiting | Phase 1 | 2025-12-24 | NCT06022029 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| OncoNano Medicine, Inc. | 1 |
16 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Allegheny Health Network | Pittsburgh | United States | 13 |
| BRCR Global | Tamarac | United States | 3 |
| California Research Institute | Los Angeles | United States | 15 |
| Cancer Care Wollongong | Wollongong | Australia | 7 |
| Gabrail Cancer Center Research | Canton | United States | 26 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Ohio State University | Columbus | United States | 169 |
| Princess Alexandra Hospital | Metro South Health | Woolloongabba | Australia | 1 |
| Southern Oncology Clinical Research Unit | Bedford Park | Australia | 1 |
| St John of God Subiaco Hospital | Subiaco | Australia | 12 |
| St Vincent's Hospital | Darlinghurst | Australia | 9 |
| Tasman Oncology Research | Southport | Australia | 8 |
| University of Texas Southwestern Medical Center | Dallas | United States | 249 |
| University of the Sunshine Coast Clinical Trials | Buderim | Australia | 1 |
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |
| Virginia Cancer Specialists, PC | Fairfax | United States | 35 |